Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single Dose, Open-Label, Randomized Two-Period Crossover Study in Healthy Young Subjects to Assess the Absolute Bioavailability of Tasimelteon (HETLIOZ™)

NCT02130999 is registered in ClinicalTrials.gov with Vanda Pharmaceuticals as lead sponsor.

NCT NCT02130999
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02130999 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single Dose, Open-Label, Randomized Two-Period Crossover Study in Healthy Young Subjects to Assess the Absolute Bioavailability of Tasimelteon (HETLIOZ™)
Lead sponsor
Vanda Pharmaceuticals
Phase
Phase 4
Overall status
Completed
Start date
May 31, 2014
Completion date
May 31, 2014
Enrollment
14 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

non-24-hour-sleep-wake disorder